|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2003-5-2
|
|
pubmed:abstractText |
A substantial proportion of HIV-1-infected individuals are intravenous drug users (i.v.DUs) who abuse opiates. Opioids induce a number of immunomodulatory effects that may directly influence HIV-1 disease progression. In the present report, we have investigated the effect of opioids on the expression of the major HIV-1 coreceptors CXCR4 and CCR5. For these studies we have focused on opiates which are ligands for the mu-opioid receptor. Our results show that DAMGO, a selective mu-opioid agonist, increases CXCR4 and CCR5 expression in both CD3(+) lymphoblasts and CD14(+) monocytes three- to fivefold. Furthermore, DAMGO-induced elevation of HIV-1 coreceptor expression translates into enhanced replication of both X4 and R5 viral strains of HIV-1. We have confirmed the role of the mu-opioid receptor based on the ability of a mu-opioid receptor-selective antagonist to block the effects of DAMGO. We have also found that morphine enhances CXCR4 and CCR5 expression and subsequently increases both X4 and R5 HIV-1 infection. We suggest that the capacity of mu-opioids to increase HIV-1 coreceptor expression and replication may promote viral binding, trafficking of HIV-1-infected cells, and enhanced disease progression.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/DNA Primers,
http://linkedlifedata.com/resource/pubmed/chemical/Enkephalin, Ala(2)-MePhe(4)-Gly(5)-,
http://linkedlifedata.com/resource/pubmed/chemical/HIV Core Protein p24,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, CCR5,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, CXCR4,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Opioid, mu
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0042-6822
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
25
|
|
pubmed:volume |
309
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
99-107
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:12726730-Base Sequence,
pubmed-meshheading:12726730-DNA Primers,
pubmed-meshheading:12726730-Enkephalin, Ala(2)-MePhe(4)-Gly(5)-,
pubmed-meshheading:12726730-Gene Expression Regulation,
pubmed-meshheading:12726730-HIV Core Protein p24,
pubmed-meshheading:12726730-HIV Long Terminal Repeat,
pubmed-meshheading:12726730-HIV-1,
pubmed-meshheading:12726730-Humans,
pubmed-meshheading:12726730-Polymerase Chain Reaction,
pubmed-meshheading:12726730-Receptors, CCR5,
pubmed-meshheading:12726730-Receptors, CXCR4,
pubmed-meshheading:12726730-Receptors, Opioid, mu,
pubmed-meshheading:12726730-Virus Replication
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Mu-opioid modulation of HIV-1 coreceptor expression and HIV-1 replication.
|
|
pubmed:affiliation |
Department of Microbiology and Immunology, Center for Substance Abuse Research, and the Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, PA 19140, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|
